| ●Editorial | Fukushima M | 4-5 | Full text | |
| ●TRI 10th Anniversary Symposium 1st World Centenarian Initiative Overcoming neuronal system refractory diseases: The current situation and future prospects for the development of innovative therapies for spinal cord injury Organized by：Translational Research Informatics Center, Foundation for Biomedical Research and Innovation Co-organized by：Association for Preventive Medicine of Japan | 7-63 | Abstract | ||
| Opening remarks | Fukushima M | 9-10 | ||
| Activities of Japan Spinal Cord Foundation, what patients think, and hope for developments of new therapies | Ohama M | 11-4 | ||
| The current situation of clinical trials on stem cell therapy for spinal cord injury in the world | Omae K | 15-7 | ||
| Spinal cord injury ─ Pathophysiology and requisites for a new therapeutic approach ─ | Yoshimine T | 18-22 | ||
| Leading edge of HAL® and medical challenges | Sankai Y | 23-8 | ||
| HAL® clinical trial in Germany for patients with spinal cord injury | Schildhauer TA | 29-30 | ||
| Basic strategy for HAL® medical application in physician-initiated, GCP-regulated clinical studies for brain, spinal cord, neuro-muscular disorders | Nakajima T | 31-8 | ||
| Basic study using bone marrow stromal cells for spinal cord injury | Ide C | 39-45 | ||
| The clinical trial of spinal cord regeneration therapy by autologous bone marrow-derived cells | Suzuki Y | 46-9 | ||
| Autologous bone marrow mesenchymal stem cell therapy for spinal cord injury | Yamashita T | 50-4 | ||
| Olfactory mucosal autografts for chronic complete spinal cord injury | Iwatsuki K | 55-9 | ||
| Panel discussion | 60-1 | |||
| Summation and closing remarks: Future vision for spinal cord injury treatments | Fukushima M | 62-3 | ||
| ●Translational Research Center Workshop Management & acceleration strategies of translational researches Organized by：Translational Research Informatics Center, Foundation for Biomedical Research and Innovation | 65-105 | Abstract | ||
| Opening remarks: Welcome to this workshop | Saruta T | 67 | ||
| National strategies to promote translational researches in Japan | Inoue T | 68-71 | ||
| Reports on visits to translational research centers in US | Nagai Y | 72-9 | ||
| Translational research initiatives in Singapore: Singapore’s biomedical initiative | Koh S | 80-6 | ||
| Translational research initiatives in Germany: Experiences on cell processing services | Schmiedeknecht G | 87-94 | ||
| Inserm Transfert: A key to access French excellence in biomedical research | Godard A | 95-102 | ||
| General discussion | 103-4 | |||
| Closing remarks | Fukushima M | 105 | ||
| ●Articles | ||||
| Clinical development of metreleptin for lipodystrophy | Ito T，Tada H， Tanaka S，et al． | 107-17 | Abstract | |
| Information disclosure on clinical trials by the national registries and regulatory agencies in Japan, US, and EU | Hoshi J，Fujii H， Takasaki K，et al． | 119-26 | Abstract | |
| The consideration about the file name of the unified form in the application of electromagnetic records of Clinical Trial-related Documents | Wakai S，Yamamoto M， Kusuoka H | 127-31 | Abstract | |
| ●Translation | ||||
| The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis | Ibargoyen-Roteta N， Gutiérrez-Ibarluzea I， Rico-Iturrioz R，et al． (trans. by Aihara M) | 133-47 | Full text | |
| ●Forum | ||||
| My proposal for conducting clinical trials at the phase III & IV, after reading the articles on Tamiflu appeared in Swiss Newspapers | Suzuki S | 149-51 | ||
| ●Instructions for authors［Japanese］＆［English］ | 153-61 | Full text | ||
| ●Editor’s note | Kageyama S | 163 | Full text | |